VIRONIKA RECEIVES PHASE I SBIR GRANT FROM NIH TO DEVELOP A NOVEL STABLE AND TUNABLE GENE THERAPY

Vironika, LLC, received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop a novel delivery system for gene therapy.

“We are very excited to have secured funding for the development of a novel gene therapy delivery system utilizing our expertise and resources in virology,” says Pieter van den Heuvel, Ph.D., Principal Investigator.

The grant will allow Vironika to develop a novel delivery system for gene therapy, superior to current systems due to specific viral components which will allow for more stable and tunable gene expression.

 

Vironika, LLC, is a privately held company founded in 2009 by Paul Lieberman, Ph.D.  Dr. Lieberman is a full Professor at the Wistar Institute in Philadelphia.